US › Healthcare

Celularity Inc (CELU)

US · Healthcare · Biotechnology

$0.70+6.54%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$4.1M
Revenue YoY
-77.4%
Net profit
$-24.4M
Profit YoY
-83.3%
EPS
$-0.85
Net margin
-593.6%

Key statistics

Market cap
$18.4M
Forward P/E
0.0
P/B
9.89
Book value
$-1.32
EPS (TTM)
$-3.59
52-week high
$4.31
52-week low
$0.56
50-day MA
$0.78
200-day MA
$1.24
Beta
0.54

Analyst view

Analysts rate Celularity Inc a buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $2.50.

Shareholding

Insiders
37.18%
Institutions
12.76%

Largest institutional holders

FundStake
C V Starr & Co Inc2.64%
Vanguard Capital Management, LLC2.15%
Geode Capital Management, LLC0.66%
BlackRock Inc0.44%
Vanguard Fiduciary Trust Co0.28%
State Street Corp0.20%
Valmark Advisers, Inc.0.17%
Northern Trust Corp0.15%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Celularity Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.